Elara Pharmaservices Limited

Elara Pharmaservices Limited is a private limited company incorporated on 17 April 2012, headquartered at The Barn Holly Berry House, Rough Park, Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ, United Kingdom. (find-and-update.company-information.service.gov.uk) The company specializes in management consultancy activities, particularly focusing on the pharmaceutical sector. It offers contract Qualified Person (QP) and technical support services, facilitating the release of non-sterile human and veterinary medicines to the market.

Elara Pharmaservices Limited holds a Manufacturer's Authorisation (ManA) from the Medicines and Healthcare products Regulatory Agency (MHRA), authorisation number UK MIA 41203, granted on 18 March 2025. (cms.mhra.gov.uk) This authorisation permits the company to import medicinal products, including both human and veterinary medicines, into the United Kingdom. The company's operations are supported by a team of directors, including Mr. Kafait Ali, Mr. Massimo Cunico, and Mrs. Joanne Lindsey Bunyan.

Elara Pharmaservices Limited operates multiple facilities to support its distribution network. These include sites at Iron Farm, 7 Grimesgate, Diseworth, Derby, DE74 2QD, and 5 Garden Court, Lockington Hall, Main Street, Lockington, Derby, DE74 2RH. (cms.mhra.gov.uk) While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's authorisations indicate a structured approach to the importation and distribution of medicinal products within the United Kingdom.

Elara Pharmaservices Limited functions as an importer and distributor within the United Kingdom's pharmaceutical supply chain. By holding a Manufacturer's Authorisation (ManA) and a Manufacturer's Import Authorisation (MIA), the company is authorised to import and distribute medicinal products, including both human and veterinary medicines. (cms.mhra.gov.uk) This authorisation underscores its role in ensuring the availability of imported pharmaceutical products in the UK market.

Elara Pharmaservices Limited's sourcing strategy exhibits a high degree of concentration, with a total import value of $2.5 million USD from India across 50 shipments. The top five products imported are Valsartan ($1.9 million, 76% of total imports) and Azathioprine ($600,000, 24% of total imports). This concentration indicates a strategic focus on specific therapeutic areas, particularly cardiovascular and immunosuppressant medications.

The company's reliance on a limited number of products suggests a targeted approach to meet specific market demands. However, this concentration also implies potential risks associated with supply chain disruptions or regulatory changes affecting these products. The stability of the relationship with Indian suppliers, such as Jubilant Generics Limited, which accounts for 93.5% of the total import value, is crucial for maintaining a consistent supply chain.

Elara Pharmaservices Limited's supply chain resilience is influenced by its sourcing strategy, which is heavily concentrated on a few products and suppliers. The company's reliance on Jubilant Generics Limited for the majority of its imports indicates a strong partnership but also exposes it to risks if this supplier faces operational challenges. The limited number of unique formulations imported (345) suggests a focused product range, which may impact the company's ability to adapt to changing market demands.

To enhance supply chain resilience, Elara Pharmaservices Limited could consider diversifying its supplier base and expanding its product portfolio. Engaging with additional suppliers and incorporating a broader range of formulations could mitigate risks associated with supplier dependency and market fluctuations.

Elara Pharmaservices Limited's concentrated sourcing pattern positions it as a specialized importer focusing on specific therapeutic areas, particularly cardiovascular and immunosuppressant medications. This strategic focus allows the company to develop expertise and potentially negotiate better terms with suppliers. However, the high dependency on a limited number of products and suppliers may expose the company to risks related to supply chain disruptions, regulatory changes, or shifts in market demand.

For Indian exporters, this concentration presents an opportunity to become key suppliers for Elara Pharmaservices Limited by offering high-quality products in the cardiovascular and immunosuppressant categories. Establishing strong relationships with the company could lead to a stable and long-term partnership, provided they can meet the required quality standards and regulatory compliance.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the regulatory authority overseeing pharmaceutical imports into the United Kingdom. The MHRA is responsible for ensuring that medicines and medical devices meet appropriate standards of safety, quality, and efficacy. (cms.mhra.gov.uk)

Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012 (SI 2012/1916), which consolidates and updates previous regulations. This legislation outlines the requirements for the importation, distribution, and sale of medicinal products in the UK. (cms.mhra.gov.uk)

The marketing authorisation pathway for Indian generics involves obtaining a UK marketing authorisation, which can be achieved through the European Medicines Agency (EMA) or the MHRA. The process includes demonstrating that the generic product is bioequivalent to the reference product and complies with Good Manufacturing Practice (GMP) standards.

Import licensing requirements for pharmaceutical products in the UK are governed by the Human Medicines Regulations 2012. Importers must hold a valid Manufacturer's Import Authorisation (MIA) issued by the MHRA. Elara Pharmaservices Limited holds MIA 41203, authorising it to import medicinal products into the UK. (cms.mhra.gov.uk)

Good Manufacturing Practice (GMP) certificates are essential for ensuring the quality and safety of imported medicines. The MHRA recognises GMP certificates from countries with equivalent standards, including those issued by the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Elara Pharmaservices Limited's authorisation indicates compliance with GMP standards, as evidenced by the MHRA's inspection and certification. (cms.mhra.gov.uk)

Imported pharmaceutical products must undergo batch testing to ensure they meet the required quality standards. The MHRA conducts inspections to verify compliance with GMP and other regulatory requirements. (cms.mhra.gov.uk)

Stability requirements for medicinal products are outlined in the British Pharmacopoeia (BP), which provides specifications for the quality of medicines. Labeling language requirements stipulate that labels must be in English, ensuring clear communication with healthcare professionals and patients. Serialization mandates are part of the EU Falsified Medicines Directive, which aims to prevent counterfeit medicines from entering the supply chain.

Between 2024 and 2026, the UK has implemented several regulatory changes affecting pharmaceutical imports. Post-Brexit, the UK has established its own regulatory framework, with the MHRA taking over responsibilities previously held by the EMA. This includes the introduction of the UK Conformity Assessed (UKCA) mark, replacing the CE mark for medical devices. Additionally, the UK has updated its import licensing requirements and GMP standards to align with international best practices.

Elara Pharmaservices Limited's focus on importing cardiovascular and immunosuppressant medications aligns with the therapeutic areas of Valsartan and Azathioprine, which constitute the majority of its imports. This strategic focus suggests an in-depth understanding of these therapeutic areas and a commitment to meeting the specific needs of the UK market.

The market demand for these products is driven by the prevalence of cardiovascular diseases and conditions requiring immunosuppression in the UK. By concentrating on these areas, Elara Pharmaservices Limited can leverage its expertise to provide high-quality, essential medicines to healthcare providers and patients.

Elara Pharmaservices Limited's sourcing strategy is centred on importing finished pharmaceutical formulations from India, focusing on specific therapeutic categories. This approach allows the company to offer a targeted product range that meets the needs of the UK market.

India's well-established pharmaceutical industry, known for its adherence to international quality standards, makes it a reliable source for these products. By importing from India, Elara Pharmaservices Limited can ensure a consistent supply of high-quality medicines while benefiting from competitive pricing.

Based on its product mix, Elara Pharmaservices Limited serves the wholesale distribution segment of the UK pharmaceutical market. By importing and distributing essential medicines, the company plays a crucial role in ensuring the availability of these products to healthcare providers and patients across the country.